Growth driven by a focus on revenue, magnesium component revenue and EBITDA
First written in FY2024. 2 of 4 entries say "Reframed", first in FY2025. Latest entry: 2026-06-30.
No other company in this theme has enough history to compare yet.
- 2026-06-30RestatedManagement Planning
「While emphasizing higher sales, we have positioned “magnesium-component sales (Note 1)” and “EBITDA (Note 2)” as important indicators and aim to increase corporate value by expanding our operating platform.」
The company reiterated that magnesium-component sales and EBITDA are important indicators. - FY2026ReframedAnnual report
「We recognize that the Group is still in the process of growth, and securing a higher growth rate is our top priority. Accordingly, while placing emphasis on increasing “revenue,” we have positioned “magnesium-part revenue” and “EBITDA” as important indicators.」
The key-indicator wording, changed to “ordinary profit” in the previous period, has returned to “magnesium-part revenue” and “EBITDA.” - FY2025ReframedAnnual report
「While placing emphasis on increasing “revenue,” we have positioned “ordinary profit” as an important indicator in order to sustain growth and aim to increase corporate value by expanding our business platform.」
The key-indicator wording has changed from “magnesium-part revenue” and “EBITDA” in the previous disclosure to “ordinary profit” in the current explanation of objective indicators. - FY2024First statedAnnual report
「While placing emphasis on increasing “revenue,” we have positioned “magnesium-part revenue” and “EBITDA” as important indicators and aim to increase corporate value by expanding our business platform.」
No specific numerical targets or deadlines are presented, but the relationship between key indicators and expansion of the business platform is stated.